Understanding Risks and Durability of CAR T-Cell Therapies

This chapter examines the FDA's recent concerns about secondary malignancies linked to CAR T-cell therapies, focusing on both common and rare malignancies. It also explores ongoing research into the durability of treatment benefits and the implications for patients with extensive chemotherapy backgrounds.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.